Home›Companies›Enterprise Software›nPhase

nPhase, Inc.

nPhase combines study data management and statistical computing in an AI-based platform for life sciences.

Updated Nov 18, 2026·Latest SEC filing Nov 18, 2026·Suggest an edit

About nPhase

nPhase helps pharmaceutical sponsors and research organizations manage clinical study data and prepare it for regulatory submission. Its software replaces scattered vendor tools with one system that uses artificial intelligence for data management and statistical computing.

By 2025, REDCap Cloud had become a global clinical data management system serving more than 500 customers. They included 75% of the top 20 pharmaceutical companies and all five top contract research organizations. nPhase is based in Atlantic Beach, Florida. Mark Lama is its chief financial officer.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Oct 13, 2026Nov 18, 2026$15,000,000of $30.0M target2$7.5MEquity, OptionsRule 506(b)Form D ↗
May 31, 2018Jun 8, 2018$1,530,000of $1.5M target11$139KEquity, Options, Securities on exerciseRule 506(b)Form D ↗
Jun 28, 2017Jul 17, 2017$1,608,340of $1.6M target10$160KEquity, Options, Securities on exerciseRule 506(b)Form D ↗
Dec 22, 2015Jan 5, 2016$1,505,000of $2.0M target4$376KEquity, Options, Securities on exerciseRule 506(b)Form D ↗
Total, four offerings$19,643,340

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on nPhase's Form D filed Nov 18, 2026.

SC
Scott Climes
Executive officer and director
On every Form D that nPhase has filed: 4 filings, from Jan 5, 2016 to Nov 18, 2026.
ML
Mark Lama
CFO and director
On every Form D that nPhase has filed: 4 filings, from Jan 5, 2016 to Nov 18, 2026.
AB
Alan Bentley
Director
On every Form D that nPhase has filed: 4 filings, from Jan 5, 2016 to Nov 18, 2026.
BW
Ben Walton
Director
On every Form D that nPhase has filed: 4 filings, from Jan 5, 2016 to Nov 18, 2026.
LM
Levi Malik
Director · of Viking Global Investors, which led the Series D round [8][6]
First appears on the Form D that nPhase filed on November 18, 2026; on 1 of its 4 filings.
TM
Trygve Mikkelsen
Director
First appears on the Form D that nPhase filed on July 17, 2017; on 3 of its 4 filings.
Trygve Mikkelsen appears on 8 Form D filings at 2 companies:
  • Best Response Strategies, director: Nov 17, 2016 · Jun 12, 2017 (amended) · Aug 24, 2017 · Jan 2, 2018 (amended) · May 23, 2019
  • nPhase, director: Jul 17, 2017 · Jun 8, 2018 · Nov 18, 2026
JR
Jaya Rao
Executive officer
First appears on the Form D that nPhase filed on November 18, 2026; on 1 of its 4 filings.

Earlier filings also listed

  • Jaya Prakash Guda · executive officer
    Last listed on the Form D that nPhase filed on June 8, 2018; on 3 of its 4 filings.
  • Vic Gatto · director
    Last listed on the Form D that nPhase filed on January 5, 2016; on 1 of its 4 filings.

Who Invested in nPhase

Scroll table to see all columns →

AnnouncedRoundAmountLeadOther investorsOn the Form DSource
Nov 2, 2026Series D$30 millionViking Global Investors—First sale Oct 13, 2026, 20 days before the announcement; $15,000,000 of $30,000,000 from 2 investors. [2][6]

Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.

Why Investors Backed nPhase

nPhase sees disconnected vendor systems as a barrier for clinical research teams. Viking Global Investors backed global expansion as a top-five sponsor used the platform to migrate more than 90 live studies and replace 13 systems. [1][6]

Origin and Team

In 2019, nPhase entered a licensing collaboration with Vanderbilt to bring REDCap Cloud to academic researchers, medical technology studies and real-world evidence research. [1]

Product and Technology

UDMS 2.0 replaces multiple legacy systems with one end-to-end clinical data-management platform. SCE is a statistical computing environment built for life sciences. The platform stores each AI output in an unchangeable snapshot for audits. [1]

At launch, nPhase said its agent-based statistical computing environment turns raw trial data into submission files that follow Clinical Data Interchange Standards Consortium standards. It reported four times faster output with 80% fewer resources. [7]

Milestones

Scroll table to see all columns →

DateWhat happenedSourceCoverage
Sep 8, 2026nPhase launched nPhase.ai and its agent-based statistical computing environment for end-to-end clinical data management.[7]—

We wrote this summary from public statements by nPhase and its investors. It is not investment advice.

Sources

  1. CompanynPhase.ai website · linked above ↑
  2. SECnPhase Form D, filed 2026-11-18 · linked above ↑
  3. SECnPhase Form D, filed 2018-06-08 · linked above ↑
  4. SECnPhase Form D, filed 2017-07-17 · linked above ↑
  5. SECnPhase Form D, filed 2016-01-05 · linked above ↑
  6. AnnouncementBusiness Wire announcement
  7. Sourcebusinesswire.com
  8. ProfileLevi Malik at Viking Global Investors
  9. SECnPhase, Inc. filing history